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Introduction
In the past few years the use of musculoskeletal ultra-
sound (MSUS) in pediatric rheumatology has proven to
be better than clinical examination in detecting synovi-
tis. It is a simple, inexpensive, noninvasive and reprodu-
cible method that is ideal for pediatric patient. The
progress of therapy options has resulted in quick remis-
sion, reversal of inflammation and improvement of life
quality; especially with introduction of biologic therapy.
To our knowledge this a first report in assessing efficacy
of IA infliximab in children with juvenile idiopathic
arthritis (JIA) by using MSUS.
Objectives
To assess the role of MSUS in follow up of patients with
JIA treated with intaarticular (IA) infliximab injections.
Methods
IA infliximab was administered in 6 joints in four patients
with JIA. All patients were diagnosed according to ILAR
classification criteria and received first and second line
therapy (NSAID, DMARD, corticosteroids), with IA corti-
costeroids on several occasions. None of them fulfilled cri-
teria for biologic therapy but were resistant to DMARD’s.
The disease was monitored by monthly clinical assessment
(JADAS, signs of swelling, pain assessed by patient/parent
(VAS), tenderness at palpation and limitation of motion),
laboratory tests (ESR, CRP) and MSUS. The Omeract
semiquantitative grades (0-3 grades) for both B-mode and
Power-Doppler (PD) evaluation of each joint were added
and the sum was defined as the Echographic Score (ES).
Before IA infliximab (50 mg per joint) was administered,
all patients relapsed according to all the assessed factors.
Results
At the point of IA injections all 6 joints showed grade 3
synovitis in B mode and increased PD signal (3/3). There
was also an increase in JADAS, VAS and increased ESR
and/or CRP. One month after IA infliximab all patients
presented with clinical and gradual US improvement. At
the follow-up visit after three months, all of them had
grade 1 synovitis without effusion in B mode, PD signal
decreased to 0-1/3, and consequently, ES normalized in all
joints. There was also clear clinical improvement in
JADAS score, local clinical status of injected joints or in
ESR and CRP.
Conclusion
It appears that IA infliximab is very powerful and
efficacious medication in selected children with
therapy-resistant, isolated mono/oligoarticular JIA.
Furthermore, MSUS appears be a valid, sensitive-to-
change and feasible method for evaluating joint inflam-
mation, and possible outcome measure in children
with JIA treated with IA infliximab.
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